PET scan to predict treatment response in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a special PET scan (68Ga-FAPI-46) to see if it can predict how well chemotherapy plus immunotherapy (pembrolizumab) works in people with triple-negative breast cancer before surgery. It aims to help doctors understand if the treatment is effective earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have triple-negative breast cancer that has not spread to other parts of the body and has not been treated yet
- Your doctor recommends neoadjuvant therapy (chemotherapy and pembrolizumab) as standard care before surgery
- You have a tumor that can be measured on scans
- You have not had immunotherapy (like Keytruda) before
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
This trial tests if combining a special type of radiation (SFRT or short-course) with or without immunotherapy (pembrolizumab) can shrink large tumors. You will get PET scans and blood tests to see how well the treatment works. The study is for certain cancers that cannot be cured with standard treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.